We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Combination of Gene Therapy and Chemotherapy Stops Kidney Cancer in Mouse Model

By LabMedica International staff writers
Posted on 03 Jan 2011
Print article
A novel therapeutic approach combining a modified viral vector and a small molecular weight drug produced promising results in a mouse model of human kidney cancer.

Investigators at the Virginia Commonwealth University (Richmond, USA) created a unique adenovirus vector by combining the tail and shaft domains of a serotype 5 virus and the knob domain of a serotype 3 virus. This Ad.5/3 adenovirus was then loaded with the gene needed to express the cancer-killing protein MDA-7/IL-24.

The viral vector was administered to mice bearing human renal carcinoma cells (RCCs), alone or together with the drug sorafenib, a small molecular weight inhibitor of several tyrosine protein kinases. Sorafenib, which is unique in targeting the Raf/Mek/Erk pathway (MAP Kinase pathway), has already been approved by the [US] Food and Drug Administration (FDA) for the treatment of renal carcinoma.

Results published in the December 15, 2010, issue of the journal Cancer Biology & Therapy revealed that infection with the Ad.5/3-mda-7 vector caused kidney cancer cells and normal cells lining the kidneys to secrete MDA-7/IL-24. MDA-7/IL-24 quickly stopped the growth of the primary tumor. As the infected cells continued to secrete MDA-7/IL-24, it entered the blood stream and eventually stopped the growth of a second, distinct tumor not directly infected by the adenovirus. Only renal carcinoma cells were destroyed by this "toxic bystander effect”; normal cells were unaffected. Sorafenib enhanced MDA-7/IL-24 toxicity and significantly increased its antitumor effects in the mouse model.

"While further research is needed, this therapy could be a novel and effective way to treat metastatic kidney cancer and prolong patient survival,” said senior author Dr. Paul Dent, professor of biochemistry at Virginia Commonwealth University. "This is the first study to clearly define that gene therapeutic delivery of MDA-7/IL-24 in kidney cancer should be explored in the clinic, especially since we have demonstrated an established, FDA-approved drug enhances its toxicity to cancer cells.”

Related Links:
Virginia Commonwealth University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.